Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00858689
Other study ID # 010308
Secondary ID
Status Completed
Phase N/A
First received March 9, 2009
Last updated February 16, 2016
Start date October 2007
Est. completion date January 2009

Study information

Verified date February 2016
Source FRAXA Research Foundation
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment, developmental disability and autism. Minocycline is an antibiotic that has recently been used to treat the mouse model for Fragile X, and was found to reverse the structural abnormalities that are seen their brain cells. The purpose of this research study is to determine if minocycline is an effective treatment for patients with fragile X syndrome (FXS).


Description:

Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment and is also associated with a range of learning disabilities, neurological problems, such as seizures, and behavioural difficulties. For many individuals with FXS, behavioral difficulties result in severe problems within the family and community, particularly in the form of agitation, temper outbursts, hyperactivity, and aggression. These problems often require a variety of psychopharmacological and behavioural approaches. Although a variety of medications can be helpful in FXS there are no targeted interventions based on molecular abnormalities that have been studied. Defects in dendritic spine formation have been found in the brains of patients with Fragile X, suggesting these structures may represent an anatomical and physiological basis for the cognitive deficits associated with this disorder. Recent research has suggested that minocycline may have a specific benefit in the treatment of FXS. Minocycline is an antibiotic that has been found to inhibit the activity of matrix metallo-proteinase-9 (MMP-9), which is up-regulated in the hippocampus of FMR1 KO (Fragile X Mental Retardation-1 Knockout) mice and may be responsible for the immature dendritic spine profile of hippocampal neurons. Minocycline has recently been used to treat the FXS KO mouse model for Fragile X, and was found to rescue this abnormal phenotype by inducing the formation of mature dendritic spines in FMR1 KO hippocampal neurons, both in vitro and in vivo. Minocycline treated FXS KO mice also performed significantly better in the elevated maze, a cognitive performance test that measures activity and anxiety.

Exciting preclinical effects of minocycline with regard to the FXS disease model have led to this pilot proposal, which is designed to generate preliminary data that could be used to support a larger clinical trial.

The overall hypothesis is that minocycline is a specific molecular targeted treatment for FXS that will display beneficial effects on disruptive behaviour and possibly other associated features of FXS via a reduction in MMP-9 activity.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 2009
Est. primary completion date November 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 13 Years to 35 Years
Eligibility Inclusion Criteria:

- Diagnosis of FXS by clinical evaluation and confirmed by FMR1-DNA testing with presence of full mutation or mosaicism for the full mutation. Prior DNA testing reports will be accepted, when available.

- Age between 13 to 35 years inclusive at the time of informed consent.

- Male or female

- CGI-Severity Score of 4 or greater, indicative of moderate or greater severity of behavioural problems. This is a 7-point scale of clinical global impression of severity that the clinician fills out after considering all the available information on the patient, including the parent history, the examination in clinic, reports from the school and other sources.

- Score of 9 or greater on the Aberrant Behaviour Checklist - Irritability Scale (top 50th %-tile). The ABC is a global behaviour checklist implemented for the measurement of drug and other treatment effects in mentally impaired individuals. It is made up of 5 empirically derived dimensions including irritability, lethargy/withdrawal, inappropriate speech, hyperactivity, and stereotypic behaviour based on 58 items that describe various behavioural problems.

- Availability of parent and/or caregiver for all clinic visits and assessments.

- English language fluency and reading level of 6th grade or greater in one caregiver.

Exclusion Criteria:

- Allergy to minocycline.

- Kidney disease or elevated renal function tests.

- Liver disease or elevated liver function tests.

- Participants with neutropenia, anemia, or thrombocytopenia.

- History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of >1:40, as minocycline may cause a lupus-like reaction.

- Individuals who do not have a mother or caregiver who is willing to participate in the clinic visits.

- Individuals who are pregnant or at risk to become pregnant, specifically sexually active females will be excluded.

- Presence of persistent psychotic symptoms

- Subjects with symptom severity likely judged to endanger personal safety or safety of others.

- History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of >1:40, as minocycline may cause a lupus-like reaction.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Minocycline
50-100 mg PO BID for 8 weeks with an option for a 1 year extension.

Locations

Country Name City State
Canada Surrey Place Centre Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
FRAXA Research Foundation Fragile X Research Foundation of Canada

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline of ABC Irritability Subtest Score at 8 Weeks The 15-item Irritability Scale includes questions about aggression, self-injury, tantrums, agitation, and unstable mood on a scale of 0 to 45 with higher scores indicating greater severity. This scale has been successfully used in previous medication studies in children with autism and in patients with FXS and in a controlled trial of ampakine CX516 in FXS. All ABC subscales showed good reliability when used by parents and caregivers of individuals with FXS to assess behavior in the CX516 study NCT00054730, and yielded intraclass correlation coefficient (ICC) values of 0.7-0.9. Baseline and 8 weeks No
Primary ABC Irritability Subtest Score ABC Irritability subtest score was used 8 weeks No
Primary ABC Irritability Subtest Score ABC (Aberrant behavior checklist) Irritability subtest score was used 1 year No
Secondary Parent Defined Target Symptoms Scale-Visual Baseline No
Secondary Clinical Global Impression Scale Baseline No
Secondary Stanford Binet 5 (SB5) Baseline No
Secondary The Peabody Picture Vocabulary Test Third Edition (PPVT-III) Baseline No
Secondary The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Baseline No
Secondary Non-Verbal Associative Learning Task (NVALT) Baseline No
Secondary Vineland Adaptive Behaviour Scales (VABS) Baseline No
Secondary Parent Defined Target Symptoms Scale-Visual 8 weeks No
Secondary Parent Defined Target Symptoms Scale-Visual 1 year No
Secondary Clinical Global Impression Scale 8 weeks No
Secondary Clinical Global Impression Scale 1 year No
Secondary Stanford Binet 5 (SB5) 1 year No
Secondary The Peabody Picture Vocabulary Test Third Edition (PPVT-III) 8 weeks No
Secondary The Peabody Picture Vocabulary Test Third Edition (PPVT-III) 1 year No
Secondary The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 8 weeks No
Secondary The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 1 year No
Secondary Non-Verbal Associative Learning Task (NVALT) 8 weeks No
Secondary Non-Verbal Associative Learning Task (NVALT) 1 year No
Secondary Vineland Adaptive Behaviour Scales (VABS) 8 weeks No
Secondary Vineland Adaptive Behaviour Scales (VABS) 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT05418049 - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT00965432 - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 Phase 1
Completed NCT01120626 - Randomized Controlled Study of Donepezil in Fragile X Syndrome Phase 2
Completed NCT01204151 - Teaching Math Skills to Individuals With Fragile X Syndrome N/A
Active, not recruiting NCT00334971 - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT04977986 - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome Phase 3
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT03722290 - Metformin in Children and Adults With Fragile X Syndrome Phase 2
Completed NCT05030129 - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome Phase 2
Recruiting NCT05957549 - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG N/A
Recruiting NCT04141163 - Metformin in Patients With Fragile X Phase 1/Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Enrolling by invitation NCT03802799 - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Phase 2/Phase 3
Recruiting NCT05295277 - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome Phase 2
Terminated NCT01555333 - An Open Label Extension Study in Subjects With Fragile X Syndrome Phase 3